The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
Open accessAbstract
Introduction: The androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in estrogen receptor alpha (ER) negative breast cancers that retain AR. However, controversy exists regarding the role of AR, particularly in ER + tumors. Enzalutamide, an AR inhibitor that impairs nuclear localization of AR, was used to elucidate the role of AR in preclinical models of ER positive and negative breast cancer. Methods: We examined nuclear AR to ER protein ratios in primary breast cancers in relation to response to endocrine therapy. The effects of AR inhibition with enzalutamide were examined in vitro and in preclinical models of ER positive and negative breast cancer that express AR. Results: In a cohort of 192 women with ER + breast cancers, a high ratio of AR:ER (≥2.0) indicated an over four fold increased risk for failure while on tamoxifen (HR = 4.43). The AR:ER ratio had an independent effect on risk for failure above ER % staining alone. AR:ER ratio is also an independent predictor of disease-free survival (HR = 4.04, 95% CI: 1.68, 9.69; p = 0.002) and disease specific survival (HR = 2.75, 95% CI: 1.11, 6.86; p = 0.03). Both enzalutamide and bicalutamide inhibited 5-alpha-dihydrotestosterone (DHT)-mediated proliferation of breast cancer lines in vitro; however, enzalutamide uniquely inhibited estradiol (E2)-mediated proliferation of ER+/AR + breast cancer cells. In MCF7 xenografts (ER+/AR+) enzalutamide inhibited E2-driven tumor growth as effectively as tamoxifen by decreasing proliferation. Enzalutamide also inhibited DHT- driven tumor growth in both ER positive (MCF7) and negative (MDA-MB-453) xenografts, but did so by increasing apoptosis. Conclusions: AR to ER ratio may influence breast cancer response to traditional endocrine therapy. Enzalutamide elicits different effects on E2-mediated breast cancer cell proliferation than bicalutamide. This preclinical study supports the initiation of clinical studies evaluating enzalutamide for treatment of AR+ tumors regardless of ER status, since it blocks both androgen- and estrogen- mediated tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Chamberlain, N. L., Driver, E. D., & Miesfeld, R. L. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3181 · Cited by 1,156
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Doane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C., & Gerald, W. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209415 · Cited by 603
Biological Aromatization of Steroids
Ryan, K. J. (1959) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70286-x · Cited by 595
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Korpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0142 · Cited by 561
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Jia, L., Moore, N. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 405
Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., & Bhargava, R. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.159 · Cited by 401
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., Rimm, D. L., Shirley Liu, X., & Brown, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.026 · Cited by 397
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Hu, R., Dawood, S., Holmes, M. D., Collins, L. C., Schnitt, S. J., Cole, K., Marotti, J. D., Hankinson, S. E., Colditz, G. A., & Tamimi, R. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2021 · Cited by 396
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., & Tamimi, R. M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.54 · Cited by 387
Expression of androgen receptors in primary breast cancer
Park, S., Koo, J., Park, H. S., Kim, J.-H., Choi, S.-Y., Lee, J. H., Park, B.-W., & Lee, K. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp510 · Cited by 343
Wilson, V. S. (2002) · Toxicological Sciences · doi:10.1093/toxsci/66.1.69 · Cited by 341
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V, Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1122 · Cited by 307
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Robinson, J. L. L., MacArthur, S., Ross‐Innes, C. S., Tilley, W. D., Neal, D. E., Mills, I. G., & Carroll, J. S. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.216 · Cited by 300
Hall, J. M., & Korach, K. S. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0438 · Cited by 293
Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1107 · Cited by 289
A refined molecular taxonomy of breast cancer
Guedj, M., Marisa, L., de Reynies, A., Orsetti, B., Schiappa, R., Bibeau, F., MacGrogan, G., Lerebours, F., Finetti, P., Longy, M., et al. (2012) · Oncogene · doi:10.1038/onc.2011.301 · Cited by 287
Bergh, J., Jönsson, P.-E., Lidbrink, E. K., Trudeau, M., Eiermann, W., Brattström, D., Lindemann, J. P. O., Wiklund, F., & Henriksson, R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.1095 · Cited by 263
Androgens induce divergent proliferative responses in human breast cancer cell lines
Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., & Tilley, W. D. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00005-k · Cited by 245
Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
De Amicis, F., Thirugnansampanthan, J., Cui, Y., Selever, J., Beyer, A., Parra, I., Weigel, N. L., Herynk, M. H., Tsimelzon, A., Lewis, M. T., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0436-8 · Cited by 230
Panet-Raymond, V., Gottlieb, B., Beitel, L. K., Pinsky, L., & Trifiro, M. A. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00279-3 · Cited by 202
Failure of 5α-Dihydrotestosterone to initiate Sexual Behaviour in the Castrated Male Rat
MCDONALD, P., BEYER, C., NEWTON, F., BRIEN, B., BAKER, R., TAN, H. S., SAMPSOM, C., KITCHING, P., GREENHILL, R., & PRITCHARD, D. (1970) · Nature · doi:10.1038/227964a0 · Cited by 193
Kang, Z., Jänne, O. A., & Palvimo, J. J. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0245 · Cited by 193
Migliaccio, A., Di Domenico, M., Castoria, G., Nanayakkara, M., Lombardi, M., de Falco, A., Bilancio, A., Varricchio, L., Ciociola, A., & Auricchio, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0912 · Cited by 182
Poulin, R., Baker, D., & Labrie, F. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01805942 · Cited by 172
Small, E. J., & Carroll, P. R. (1994) · Urology · doi:10.1016/0090-4295(94)90092-2 · Cited by 171
Dimitrakakis, C., & Bondy, C. (2009) · Breast Cancer Research · doi:10.1186/bcr2413 · Cited by 167
Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole
Macedo, L. F., Guo, Z., Tilghman, S. L., Sabnis, G. J., Qiu, Y., & Brodie, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3984 · Cited by 158
Hall, R. E., Birrell, S. N., Tilley, W. D., & Sutherland, R. L. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90424-3 · Cited by 131
Positive Feedback Activation of Estrogen Receptors by the CXCL12-CXCR4 Pathway
Sauvé, K., Lepage, J., Sanchez, M., Heveker, N., & Tremblay, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4924 · Cited by 123
Søreide, J. A., Lea, O. A., Varhaug, J. E., Skarstein, A., & Kvinnsland, S. (1992) · PubMed · Cited by 105
Androgen receptor as a targeted therapy for breast cancer.
Garay, J. P., & Park, B. H. (2012) · Europe PMC (PubMed Central) · Cited by 105
Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues
Recchione, C., Venturelli, E., Manzari, A., Cavalleri, A., Martinetti, A., & Secreto, G. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00017-t · Cited by 101
Simon, W. E., Albrecht, M. C., Trams, G., Dietel, M., & Hölzel, F. (1984) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/73.2.313 · Cited by 92
Cops, E. J., Bianco‐Miotto, T., Moore, N. L. T., Clarke, C. L., Birrell, S. N., Butler, L. M., & Tilley, W. D. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.10.014 · Cited by 78
Garay, J. P., Karakas, B., Abukhdeir, A. M., Cosgrove, D., Gustin, J. P., Higgins, M. J., Konishi, H., Konishi, Y., Lauring, J. D., Mohseni, M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3112 · Cited by 65
Moore, N. L. T., Buchanan, G., Harris, J. M., Selth, L. A., Bianco‐Miotto, T., Hanson, A. R., Birrell, S. N., Butler, L. M., Hickey, T. E., & Tilley, W. D. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0065 · Cited by 61
Harvell, D. M. E., Spoelstra, N. S., Singh, M., McManaman, J. L., Finlayson, C. A., Phang, T. L., Trapp, S., Hunter, L., Dye, W. W., Borges, V. F., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9897-4 · Cited by 59
Self-citationMagklara, A., Brown, T. J., & Diamandis, E. P. (2002) · International Journal of Cancer · doi:10.1002/ijc.10520 · Cited by 58
Morris, K. T., Toth‐Fejel, S., Schmidt, J., Fletcher, W. S., & Pommier, R. F. (2001) · Surgery · doi:10.1067/msy.2001.118378 · Cited by 54
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor
Kasina, S., & Macoska, J. A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.12.015 · Cited by 52
Swerdloff, R. S., & Wang, C. (1998) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(98)80267-x · Cited by 52
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy
Gallicchio, L. M., MacDonald, R., Wood, B., Rushovich, E., & Helzlsouer, K. J. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1611-2 · Cited by 36
Harvell, D. M. E., Richer, J. K., Singh, M., Spoelstra, N. S., Finlayson, C. A., Borges, V. F., ELIAS, A. D., & Horwitz, K. B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9923-6 · Cited by 33
Self-citationFailure of 5α-Dihydrotestosterone To Elicit Estrous Behavior in the Ovariectomized Rabbit
Beyer, C., MCDONALD, P., & VIDAL, N. (1970) · Endocrinology · doi:10.1210/endo-86-4-939 · Cited by 31
Spinola, P. G., Marchetti, B., Mérand, Y., Bélanger, A., & Labrie, F. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01811241 · Cited by 22
Cited by
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Male breast cancer: a disease distinct from female breast cancer
Gucalp, A., Traina, T. A., Eisner, J. R., Parker, J. S., Selitsky, S. R., Park, B. H., Elias, A. D., Baskin-Bey, E. S., & Cardoso, F. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4921-9 · Cited by 392
Self-citationGenetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 262
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., Jindal, S., Hui, M., Finlay-Schultz, J., Ebrahimie, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01168-7 · Cited by 257
Metadata
- Authors
- Cochrane, D. R., Bernales, S., Jacobsen, B. M., Cittelly, D. M., Howe, E. N., D’Amato, N. C., Spoelstra, N. S., Edgerton, S. M., Jean, A., Guerrero, J., Gómez, F., Medicherla, S., Alfaro, I. E., McCullagh, E., Jedlicka, P., Torkko, K. C., Thor, A. D., Elias, A. D., Protter, A. A., & Richer, J. K.
- Venue
- Breast Cancer Research
- Published
- 2014-01-22
- Volume
- 16
- Issue
- 1
- Pages
- R7-R7
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W2107617686
- Cited by
- 427
- References
- 53
- FWCI
- 23.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.